A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group,
Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance
Combination Therapy with Guselkumab and Golimumab in Participants with Moderately
to Severely Active Crohn’s Disease